These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 2522811)

  • 1. High-dose medroxyprogesterone acetate in advanced breast cancer. Clinical and pharmacokinetic study with a combined oral and intramuscular regimen.
    Becher R; Miller AA; Höffken K; Gerhold U; Hirche H; Schmidt CG
    Cancer; 1989 May; 63(10):1938-43. PubMed ID: 2522811
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral versus intramuscular high-dose medroxyprogesterone acetate (HD-MPA) in advanced breast cancer. A randomized study of the Belgian Society of Medical Oncology.
    Paridaens R; Becquart D; Michel J; Vanderlinden B; Longueville J; Majois F; Beauduin M; Focan C; Wildiers J; Bernheim J
    Anticancer Res; 1986; 6(5):1089-94. PubMed ID: 2948441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral versus im administration of high-dose medroxyprogesterone acetate in pretreated patients with advanced breast cancer.
    Beex L; Burghouts J; van Turnhout J; Breed W; Hillen H; Holdrinet A; Boetius G; Hoogendoorn G; Doesburg W; Verhulst M
    Cancer Treat Rep; 1987 Dec; 71(12):1151-6. PubMed ID: 3690524
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized trial of low- versus high-dose medroxyprogesterone acetate in the induction treatment of postmenopausal patients with advanced breast cancer.
    Cavalli F; Goldhirsch A; Jungi F; Martz G; MermillodB ; Alberto P
    J Clin Oncol; 1984 May; 2(5):414-9. PubMed ID: 6233398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medroxyprogesterone acetate at very high doses in postmenopausal advanced breast cancer patients.
    Pannuti F; Longhi A; Martoni A; Piana E; Baroni M
    Chemioterapia; 1987 Dec; 6(6):396-8. PubMed ID: 2963702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An evaluation of high-dose medroxyprogesterone acetate (MPA) therapy in women with advanced breast cancer.
    Johnson JR; Priestman TJ; Fotherby K; Kelly KA; Priestman SG
    Br J Cancer; 1984 Sep; 50(3):363-6. PubMed ID: 6235831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral high-dose medroxyprogesterone acetate versus tamoxifen. A randomized crossover trial in postmenopausal patients with advanced breast cancer.
    van Veelen H; Willemse PH; Tjabbes T; Schweitzer MJ; Sleijfer DT
    Cancer; 1986 Jul; 58(1):7-13. PubMed ID: 2939943
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The pharmacokinetics of medroxyprogesterone acetate following two different loading dose schedules in advanced carcinoma of the breast.
    Canney PA; Dowsett M; Priestman TJ
    Br J Cancer; 1988 Jul; 58(1):73-6. PubMed ID: 2971386
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Response to medroxyprogesterone acetate (NSC-26386) as secondary hormone therapy for metastatic breast cancer in postmenopausal women.
    Klaassen DJ; Rapp EF; Hirte WE
    Cancer Treat Rep; 1976 Mar; 60(3):251-3. PubMed ID: 1260780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and pharmacodynamics of medroxyprogesterone acetate in advanced breast cancer patients.
    Etienne MC; Milano G; Frenay M; Renee N; Francois E; Thyss A; Schneider M; Namer M
    J Clin Oncol; 1992 Jul; 10(7):1176-82. PubMed ID: 1535103
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Phase II study of medroxyprogesterone acetate in advanced breast cancer].
    Ueno K; Ogawa M; Horikoshi N; Inoue K; Mukaiyama T; Nakamura T; Ito Y; Imajo K; Ozeki H
    Gan To Kagaku Ryoho; 1986 Oct; 13(11):3198-202. PubMed ID: 2946264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Oral high doses of medroxyprogesterone acetate (MPA) in the treatment of advanced phases of breast and endometrial cancer].
    Bernardo-Strada MR; Imparato E; Aspesi G; Pavesi L; Robustelli Della Cuna G
    Minerva Med; 1980 Nov; 71(44):3241-6. PubMed ID: 7454090
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Oral high-dose medroxyprogesterone acetate (MPA) in the treatment of advanced and recurrent breast cancer: a dose-response evaluation].
    Tominaga T; Izuo M; Nomura Y; Kubo K; Abe O; Enomoto K; Takatani O
    Gan To Kagaku Ryoho; 1982 Nov; 9(11):1994-2004. PubMed ID: 6223590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral route administration of medroxyprogesterone acetate (MAP) at high doses in the treatment of advanced breast cancer: clinical results.
    Guarnieri A; Tucci E; D'Aniello C; Carli A; Mariani L; De Stefano A; Nardi P
    Chemioterapia; 1984 Oct; 3(5):320-3. PubMed ID: 6241848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose medroxyprogesterone acetate (MPA) treatment in advanced breast cancer. A review.
    Ganzina F
    Tumori; 1979 Oct; 65(5):563-85. PubMed ID: 390798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral high-dose progestins as treatment for advanced breast cancer.
    Lundgren S; Kvinnsland S; Utaaker E
    Acta Oncol; 1989; 28(6):811-6. PubMed ID: 2532917
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Therapeutic effects of medroxyprogesterone acetate in recurrent or advanced breast cancer].
    Yoshida M; Murai H; Miura S
    Gan To Kagaku Ryoho; 1985 Mar; 12(3 Pt 1):516-23. PubMed ID: 3159345
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alternating sequential endocrine therapy: tamoxifen and medroxyprogesterone acetate versus tamoxifen in postmenopausal advanced breast cancer patients.
    Beltrán M; Alonso MC; Ojeda MB; Izquierdo A; Ferrer J; Picó C; Anglada L; Catalán G; Batiste-Alentorn E; Tusquets I
    Ann Oncol; 1991 Jul; 2(7):495-9. PubMed ID: 1832944
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The elevation of serum iron level with oral administration of medroxyprogesterone acetate (MPA) in patients with breast cancer].
    Kadota K; Wada T; Watatani M; Houjou T; Mori N; Yasutomi M
    Gan To Kagaku Ryoho; 1991 May; 18(6):983-7. PubMed ID: 1827574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical investigation of oral high-dose medroxyprogesterone acetate (MPA) in advanced breast cancer--double-blind controlled study: Japanese Group for MPA Treatment of Breast Cancer].
    Izuo M; Tominaga T; Yoshida M; Nomura Y; Abe O; Enomoto K; Kubo K; Takatani O
    Gan No Rinsho; 1985 May; 31(5):487-93. PubMed ID: 3160869
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.